%609041
Table of Contents
Cytogenetic location: 10q22.1-q24.1 Genomic coordinates (GRCh38) : 10:68,800,001-97,500,000
Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
---|---|---|---|---|
10q22.1-q24.1 | Spastic paraplegia 27, autosomal recessive | 609041 | AR | 2 |
Meijer et al. (2004) reported a large French Canadian family in which 7 of 14 sibs had a pure form of spastic paraplegia (SPG) with adult onset (25 to 45 years). All affected individuals had moderate to severe lower limb spastic paraparesis with hyperreflexia, extensor plantar responses, and spastic bladders. There was also moderate to severe decrease of vibration sense in the feet. Two individuals had dysarthria. Only 1 patient was wheelchair-bound. Nerve conduction studies showed normal sensory and compound muscle action potentials, but somatosensory-evoked potentials were abnormal in 2 patients studied.
Two-point parametric linkage analysis on the family reported by Meijer et al. (2004), under an autosomal recessive model, identified a putative disease locus, designated SPG27, on chromosome 10q22.1-q24.1 (maximum lod score of 4.49 at markers D10S580 and D10S1765). The critical disease locus spans approximately 26 Mb between markers D10S606 and D10S1758 and partially overlaps with the SPG9 (601162) locus. However, the authors noted that SPG9 is autosomal dominant and has additional neurologic features ('complicated').
Meijer, I. A., Cossette, P., Roussel, J., Benard, M., Toupin, S., Rouleau, G. A. A novel locus for pure recessive hereditary spastic paraplegia maps to 10q22.1-10q24.1. Ann. Neurol. 56: 579-582, 2004. [PubMed: 15455396, related citations] [Full Text]
SNOMEDCT: 778030005; ORPHA: 101007; DO: 0110778;
Cytogenetic location: 10q22.1-q24.1 Genomic coordinates (GRCh38) : 10:68,800,001-97,500,000
Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
---|---|---|---|---|
10q22.1-q24.1 | Spastic paraplegia 27, autosomal recessive | 609041 | Autosomal recessive | 2 |
Meijer et al. (2004) reported a large French Canadian family in which 7 of 14 sibs had a pure form of spastic paraplegia (SPG) with adult onset (25 to 45 years). All affected individuals had moderate to severe lower limb spastic paraparesis with hyperreflexia, extensor plantar responses, and spastic bladders. There was also moderate to severe decrease of vibration sense in the feet. Two individuals had dysarthria. Only 1 patient was wheelchair-bound. Nerve conduction studies showed normal sensory and compound muscle action potentials, but somatosensory-evoked potentials were abnormal in 2 patients studied.
Two-point parametric linkage analysis on the family reported by Meijer et al. (2004), under an autosomal recessive model, identified a putative disease locus, designated SPG27, on chromosome 10q22.1-q24.1 (maximum lod score of 4.49 at markers D10S580 and D10S1765). The critical disease locus spans approximately 26 Mb between markers D10S606 and D10S1758 and partially overlaps with the SPG9 (601162) locus. However, the authors noted that SPG9 is autosomal dominant and has additional neurologic features ('complicated').
Meijer, I. A., Cossette, P., Roussel, J., Benard, M., Toupin, S., Rouleau, G. A. A novel locus for pure recessive hereditary spastic paraplegia maps to 10q22.1-10q24.1. Ann. Neurol. 56: 579-582, 2004. [PubMed: 15455396] [Full Text: https://doi.org/10.1002/ana.20239]
Dear OMIM User,
To ensure long-term funding for the OMIM project, we have diversified our revenue stream. We are determined to keep this website freely accessible. Unfortunately, it is not free to produce. Expert curators review the literature and organize it to facilitate your work. Over 90% of the OMIM's operating expenses go to salary support for MD and PhD science writers and biocurators. Please join your colleagues by making a donation now and again in the future. Donations are an important component of our efforts to ensure long-term funding to provide you the information that you need at your fingertips.
Thank you in advance for your generous support,
Ada Hamosh, MD, MPH
Scientific Director, OMIM